💊 Three regenerative medicines, one of them the world's first drug derived from iPS cells, are now covered by Japan's public health insurance. On May 13, 2026, Japan's pricing authority cleared all three, and they were added to the national price list on May 20. Sticker prices run from roughly $352,000 to over $1 million per treatment. Japan's record holder is still Elevidys, listed in February 2026 at ¥304.97 million, but ultra-expensive regenerative products are now arriving in clusters rather than one at a time.

What was approved, and when

The Central Social Insurance Medical Council (中央社会保険医療協議会, or "Chuikyo") sets the price of everything Japan's public health insurance covers. All three products were added to the national drug price list on May 20, 2026, and eligible patients have been able to receive them through the universal insurance system since that date.

The three products are:

  • Amshepri (general name: ragnaprocel; Sumitomo Pharma). An iPS cell-derived treatment for Parkinson's disease.
  • Akugo Intracerebral Injection (general name: vandefitemcel; SanBio). A bone-marrow-derived stem cell therapy for chronic motor paralysis after traumatic brain injury.
  • Zolgensma Intrathecal (general name: onasemnogene abeparvovec; Novartis Pharma). A gene therapy for spinal muscular atrophy (SMA) patients aged 2 and older.

Four conventional drugs were listed the same day: a low-dose contrast agent called Amberbist, plus Sohonos for fibrodysplasia ossificans progressiva, Dojolvi for long-chain fatty acid oxidation disorders, and Inrebic for myelofibrosis. But it was the three regenerative medicines that drew attention, because of their prices.

Amshepri: the world's first iPS cell drug

Amshepri targets Parkinson's disease, a progressive neurological disorder in which the brain gradually loses the dopamine-producing neurons that help control movement. Patients experience tremors, stiffness, and slowed movement that worsen over years. Oral drugs like levodopa work well at first but lose effectiveness, and many patients eventually reach a stage where their days are shaped by the "off" periods when medication wears off.

Amshepri is a cell therapy. It starts with induced pluripotent stem cells (iPS cells), ordinary adult cells reprogrammed back to an embryonic-like state and then coaxed into another cell type. Here they are differentiated into dopamine-producing neural precursors and implanted into the putamen through stereotactic brain surgery, to replace the neurons the disease has destroyed.

Approval came on March 6, 2026 under Japan's "conditional and time-limited approval" pathway, which lets a product reach patients while additional clinical data is collected. According to Sumitomo Pharma, it is the world's first approved drug derived from iPS cells, a milestone for a technology pioneered by Kyoto University Professor Shinya Yamanaka, who won the 2012 Nobel Prize for the discovery.

The official price is ¥55,306,737 per patient (approximately $352,000) for a set of 18 vials. Sumitomo Pharma projects 133 patients at peak (fiscal year 2035) and annual sales of about ¥7.4 billion ($47 million). Sales are expected to begin in late autumn 2026, and the post-marketing study supporting a full approval application will enrol 35 patients across seven sites.

Amshepri is approved only for patients who no longer get adequate relief from existing drug therapy, including levodopa-based regimens. It is not a cure for Parkinson's disease, and long-term safety and efficacy data are still being collected.

Akugo: stem cells for traumatic brain injury

Akugo Intracerebral Injection is for adults left with chronic motor paralysis after traumatic brain injury (TBI): the limb weakness and impaired movement that persist months or years after a head trauma. According to SanBio, no treatment could meaningfully improve motor function in chronic-stage TBI patients before this one, and rehabilitation was effectively the only option.

The product is made from bone-marrow-derived mesenchymal stem cells from healthy donors, briefly modified to enhance their regenerative properties, then surgically injected into the brain near the site of injury. The cells are thought to release neurotrophic and growth factors that support the brain's own repair mechanisms.

Akugo received conditional and time-limited approval in Japan in July 2024 as the world's first cell therapy approved for traumatic brain injury, but commercialization did not go smoothly. Manufacturing problems, including reduced cell yields and a foreign matter contamination issue, delayed launch for nearly two years.

The Phase 2 STEMTRA trial behind the approval, published in Neurology, showed improvement on the Fugl-Meyer Motor Scale (a standard measure of motor recovery) at six months, sustained through 48 weeks. No new safety concerns emerged; headache was the most common adverse event.

The price, set by the cost-calculation method with a 10% marketability premium and a 10% pioneer premium, is ¥72,716,528 per dose (approximately $463,000). SanBio projects 39 patients at peak and annual sales of about ¥2.8 billion ($18 million).

Zolgensma Intrathecal: a new route for an existing gene therapy

The third drug, Zolgensma Intrathecal, is the more complicated story. Zolgensma is a one-time gene therapy for spinal muscular atrophy (SMA), a rare and devastating neuromuscular disease caused by mutations in the SMN1 gene. Without functional SMN protein, motor neurons in the spinal cord die, and patients lose the ability to move, swallow, and eventually breathe. SMA is a designated intractable disease in Japan, with 943 certificate-holders recorded in fiscal year 2024.

An intravenous (IV) version of Zolgensma has been covered in Japan since its March 2020 approval, at an official price of ¥167,077,222. It held the record as the most expensive drug covered by Japanese insurance until February 2026, when Elevidys, a gene therapy for Duchenne muscular dystrophy, was listed at ¥304,972,042. The IV version is approved only for patients under two years old.

The new intrathecal version goes directly into the spinal fluid through a lumbar puncture rather than an IV drip. It is approved for SMA patients aged 2 and older, adults included, who test negative for anti-AAV9 antibodies. According to Novartis, it was approved in Japan in April 2026 based on the STEER trial (for treatment-naive patients) and the STRENGTH trial (for patients switching from other SMA therapies), both of which showed motor function improvement or maintenance.

The intrathecal version was approved in the U.S. in November 2025 for the same indication. The Japanese price is identical to the IV version at ¥167,077,222 per patient (approximately $1.06 million), with 26 patients and ¥4.3 billion ($27 million) in annual sales projected at peak.

For SMA patients aged 2 or older who never received Zolgensma as infants, whether because they were diagnosed later or because the IV version came too late, this is the first gene therapy available to them in Japan.

Why are these drugs so expensive?

Japan prices a brand-new drug with no comparable existing product using the cost-calculation method (原価計算方式, genka keisan hōshiki). The formula adds up the manufacturer's reported costs for raw materials, labor, manufacturing, and general administration, then adds projected operating profit, distribution costs, and consumption tax. Innovation premiums can be layered on top. Amshepri and Akugo were both priced this way; Zolgensma Intrathecal was simply matched to the existing IV version.

For these three drugs in particular, several factors push the underlying cost very high:

Manufacturing is genuinely complicated. Regenerative medicines are not chemicals that can be mass-produced in a tank. Amshepri means culturing and differentiating live iPS cells; Akugo means harvesting bone marrow cells, modifying them temporarily, and expanding them in culture; Zolgensma means producing modified adeno-associated viruses carrying the SMN1 gene. According to a 2023 industry paper from the Forum for Innovative Regenerative Medicine (FIRM), this kind of production needs specialized cold-chain logistics and dedicated supply chains, and per-batch costs are high. Some batches fail entirely, and the manufacturer absorbs the loss.

R&D recovery has to happen across very few patients. A drug used by 100 million people can spread its development costs thinly. A drug for a rare disease with a few hundred eligible patients in the entire country has to recover the same kind of R&D bill from a much smaller base. Sumitomo Pharma projects just 133 Amshepri patients at peak; SanBio projects 39 patients per year for Akugo.

These drugs are one-time treatments. Unlike a chronic medication taken daily for life, Amshepri, Akugo, and Zolgensma are designed to be given once. The total lifetime cost to the system per patient may even be lower than for some long-term drugs. The size of the single bill does not change.

How Japan's insurance system protects patients

A sticker price of ¥167 million sounds catastrophic, but very few Japanese patients will ever see a bill anywhere near that figure. Japan's universal health insurance system uses several layered protections.

Cost-sharing. Under public insurance, patients pay 30% of medical costs at the window (10–20% for the elderly and young children, depending on age and income). For a ¥167 million drug at 30% cost-sharing, that is still ¥50 million, an impossible sum for most families. That is where the next mechanism kicks in.

The High-Cost Medical Expense Benefit (高額療養費制度, kōgaku ryōyōhi seido). This caps the patient's out-of-pocket payment each month based on age and income. According to the Ministry of Health, Labour and Welfare (MHLW), the current cap for a person under 70 earning roughly ¥3.7–7.7 million ($24,000–$49,000) is ¥80,100 plus 1% of the amount by which total medical costs exceed ¥267,000. On a ¥1 million monthly bill that works out to ¥87,430 (about $550), with the rest reimbursed by insurance. But because of the 1% component, a ¥167 million drug would push the same patient's monthly cap to roughly ¥1.75 million.

The Designated Intractable Disease subsidy (指定難病医療費助成制度). Both SMA and moderate-to-severe Parkinson's disease are on Japan's list of designated intractable diseases. Certified patients pay 20% rather than 30%, and their monthly out-of-pocket ceiling is set by income at between ¥2,500 and ¥30,000, with public funds covering everything above it. Traumatic brain injury is not on the list, although disability benefits and other programs may apply.

Local pediatric medical subsidies. Most municipalities provide free or nearly free medical care for children, which can further reduce out-of-pocket costs for younger patients.

Stacked together, these mechanisms usually leave a family paying somewhere between a few thousand and a few tens of thousands of yen a month for an ultra-expensive drug, not tens of millions. Exact figures depend on age, income, certification status, and municipality.

The High-Cost Medical Expense Benefit is itself mid-revision. According to MHLW, monthly caps rise from August 2026, and in August 2027 the five income brackets split into thirteen. A new annual cap is being introduced to ease the burden on long-term patients. A steeper increase proposed in 2025 was withdrawn after pushback from patient advocacy groups, including cancer patient organizations, and the rise was compressed to a maximum of roughly 38%.

Will the prices come down over time?

Japan has built-in mechanisms that can lower drug prices, though none guarantee dramatic price drops for these specific products.

Biennial price revisions. All listed drugs are reviewed every two years, with interim reviews in off-years for products where official and market prices have drifted far apart. Prices tend to fall over time as competition emerges.

Market expansion repricing (市場拡大再算定). If annual sales pass ¥15 billion ($95 million) and more than double the original projection, or pass ¥10 billion ($64 million) at more than ten times projection, the price can be cut by up to 25%. The rule is designed to claw back excess profits if a drug ends up far more widely used than the manufacturer had predicted.

For these three drugs, projected peak sales are well below the thresholds that would trigger automatic market-expansion repricing (Amshepri ¥7.4 billion, Akugo ¥2.8 billion, Zolgensma Intrathecal ¥4.3 billion). So large automatic price cuts on this mechanism are unlikely unless patient numbers far exceed projections.

Full-approval repricing. Amshepri and Akugo still hold conditional and time-limited approvals. Under that status, according to Nikkei, the price is set with only half the normal operating profit margin. When a product graduates to full approval after demonstrating efficacy in post-marketing studies, the manufacturer can apply for a recalculation, which here might push the price up rather than down.

Industry-wide pricing reforms. The Japanese government regularly debates the pricing of high-cost regenerative medicines. The FIRM industry group has argued the current framework doesn't adequately capture the value of one-time curative treatments, while patient and payer groups push for tighter cost controls. Future reforms could go in either direction.

So the answer to "will it get cheaper" is: modestly, over many years, through biennial revisions; possibly not at all in the short term; possibly the opposite after full approval. There is no equivalent of generic competition for cell and gene therapies in the near term.

From exception to fixture

When the IV form of Zolgensma joined the insurance list in 2020, it was a striking exception. In February 2026 Elevidys, a ¥304 million ($1.9 million) gene therapy for Duchenne muscular dystrophy, took the record. Three months later, three more regenerative medicines arrived at once. According to MHLW, more are in the pipeline. Ultra-expensive cell and gene therapies are turning from curiosities into regulars.

Japan's universal health insurance is one of the most generous in the world in covering treatments like these. The question for the years ahead is how to sustain that generosity, with a rapidly aging population and a shrinking workforce, as the cumulative bill grows. The High-Cost Medical Expense Benefit reforms now being phased in are part of the search for an answer.

How is it in your country?

Japan's approach is to add these drugs to universal insurance, set prices through a transparent (if contested) cost-calculation formula, then shield patients through a layered out-of-pocket cap. In the U.S., these therapies are typically negotiated with private insurers and Medicaid, often with outcomes-based contracts. In the U.K., NICE evaluates cost-effectiveness before NHS coverage. In Germany, the G-BA assesses added benefit and prices are negotiated centrally. Each system makes different trade-offs between access, sustainability, and patient burden.

If you or your family has faced the cost of a rare-disease therapy, we'd like to hear how the system worked, or didn't work, in your country.

Sources